Skip to search formSkip to main contentSkip to account menu

AC220

Known as: AC-220, AC010220 
National Institutes of Health

Related topics

Related topics

1 relation
Quizartinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Highly Cited
2015
Highly Cited
2015
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
In acute myeloid leukemia (AML), about 25–30% of patients harbor a constitutively active receptor tyrosine kinase (RTK) FLT3… 
2014
2014
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
The vast majority of acute myeloid leukemia (AML) patients harboring an FLT3-ITD mutation experience relapse within a short… 
2014
2014
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
7100 Background: The presence of FLT3-internal tandem duplication (ITD) in patients (pts) with acute myeloid leukemia (AML) is… 
Highly Cited
2013
Highly Cited
2013
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired… 
2013
2013
AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial
Introduction AC220 (Quizartinib) is a novel FLT3 inhibitor that has shown a high level of activity as monotherapy in patients… 
2013
2013
The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells.
2013
2013
Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)
FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) in acute myeloid leukemia (AML) are associated with early… 
Review
2012
Review
2012
Molecular targeted therapy in acute myeloid leukemia
The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding… 
Highly Cited
2009
Highly Cited
2009
AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.
Abstract 636 Activating mutations in the FLT3 RTK are present in ∼30% of AML patients (pts), who have a significantly worse… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)